findmyKOL
Clinical trialNCT03478514Active, not recruitingPhase 2Interventional

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

SponsorAlliance Foundation Trials, LLC.Enrollment39B Cell LymphomaMantle Cell Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The proposed study is a single-arm, multi-center, open-label phase II study of the combination of palbociclib and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination, with the primary objective of the study being to assess median PFS and the secondary objectives to include ORR, CR, DOR, OS and toxicity. Subjects will be enrolled and treated with palbociclib and ibrutinib with each cycle of therapy being 28 days. Treatment will be based on the recommended phase II dose (RP2D) from the phase I combination trial.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • City of Hope National Medical Center

    Duarte, California, United States

  • University of Maryland, Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, United States

  • St. Joseph Mercy Hospital Cancer Care Center

    Ypsilanti, Michigan, United States

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, United States

  • Weill Cornell Medical College

    New York, New York, United States

  • University of North Carolina

    Chapel Hill, North Carolina, United States

  • Ohio State University

    Columbus, Ohio, United States

  • Medical University of South Carolina - Hollings Cancer Center

    Charleston, South Carolina, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ibrutinib →Palbociclib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
11 Sept 2018
Primary completion
19 Dec 2025
Completion
30 Aug 2026
Last update posted
24 Jul 2026
Registered enrollment
39
Registry id
NCT03478514
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.